BMS-794833通过向VEGFR/Ras/CDK2通路来降低骨髓瘤中的anlotinib耐药性
Qingtao Meng1,2, Jian Han2, Peng Wang3
1Department of Orthopedics, The Second Affiliated Hospital of Dalian Medical University, Dalian 116028, China.
Journal of bone oncology
|March 27, 2024
概括
这项研究表明,BMS-794833可以通过向VEGFR/Ras/CDK2通路来克服骨髓瘤中的anlotinib耐药性. 将BMS-794833与anlotinib结合起来,可以为骨髓瘤提供协同治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 骨髓瘤是一种高度恶性骨瘤,预后不佳.
- 安洛丁尼布是一种多位氨酸激酶抑制剂 (TKI),是先进骨髓瘤的第一线治疗方法.
- 对anlotinib的耐药性是一个重大的临床挑战,需要新的治疗策略.
研究的目的:
- 调查BMS-794833在克服骨髓瘤中安洛尼布抗性的潜力.
- 阐明BMS-794833对anlotinib耐药性的作用背后的分子机制.
- 评估结合BMS-794833和anlotinib在骨髓瘤治疗中的协同治疗潜力.
主要方法:
- 细胞计数工具-8 (CCK8) 试验被用于评估药物敏感性.
- 生物信息学分析和救援实验确定了关键的信号通路.
- 在体内研究中使用基于细胞系的异种移植模型来评估治疗疗效.
主要成果:
- BMS-794833显著提高了骨髓瘤细胞对anlotinib的敏感度.
- 观察到的敏感性取决于VEGFR/Ras/CDK2通路.
- 与BMS-794833和anlotinib的联合治疗在体内显示出协同作用的治疗效果.
结论:
- 通过向VEGFR/Ras/CDK2通路,BMS-794833有效地降低了骨髓瘤中的anlotinib耐药性.
- 这项研究为使用针对VEGFR的药物与anlotinib结合使用来克服骨髓瘤中药物耐药性的理论基础.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
9.2K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K